Physician profile
Eva Gupta
NPI 1093944092
$21,058.62
in general payments reported to CMS, 2019-2025
77 companies · $5,505 in 2025
The $5,505 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $994 · 2021: $1,586 · 2022: $2,728 · 2023: $4,199 · 2024: $5,413 · 2025: $5,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $1,280 · Consulting Fee: $1,100 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,731.88 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Consulting Fee | $1,100.00 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,716.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,809.51 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $1,223.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,134.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,043.41 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Lilly USA, LLC | $896.89 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $871.75 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $754.80 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $732.55 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Eisai INC. | $670.22 | 2019-2025 | |
| Incyte Corporation | $652.31 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
| Seagen INC. | $629.78 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $570.00 | 2020-2025 | |
| Genzyme Corporation | $555.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.27 | 2019-2025 | Alunbrig, Fruzaqla, Iclusig |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $445.81 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Genentech USA, INC. | $423.39 | 2019-2025 | Venclexta, Perjeta, Phesgo |
| Daiichi Sankyo INC. | $417.44 | 2020-2025 | Enhertu |
| Glaxosmithkline, LLC. | $288.93 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $273.67 | 2020-2023 | Lumakras, Vectibix, Xgeva |
| Array Biopharma INC | $258.98 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Myriad Genetic Laboratories, INC. | $257.35 | 2022-2024 | Myrisk |
| Kite Pharma, INC. | $250.45 | 2021-2025 | Yescarta |
| Abbvie INC. | $246.74 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.87 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $179.31 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $175.23 | 2020-2025 | |
| Rigel Pharmaceuticals, INC. | $167.27 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Jazz Pharmaceuticals INC. | $166.80 | 2022-2025 | |
| Mirati Therapeutics, INC. | $159.07 | 2023-2024 | Krazati |
| Exelixis INC. | $131.83 | 2022-2025 | Cabometyx |
| Sobi, INC | $130.70 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $121.13 | 2022-2025 | Xpovio |
| Beigene USA, INC. | $119.55 | 2022-2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $114.71 | 2023-2025 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $94.75 | 2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.42 | 2020-2021 | |
| Taiho Oncology, INC. | $89.99 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $79.31 | 2024-2025 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $72.73 | 2022-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $71.64 | 2023-2025 | Onivyde, Somatuline Depot |
| Myovant Sciences INC. | $71.40 | 2021-2022 | |
| Pharmaessentia USA Corporation | $68.07 | 2023-2025 | Besremi |
| Tersera Therapeutics LLC | $67.61 | 2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $65.64 | 2021-2022 | |
| Emd Serono, INC. | $62.64 | 2022-2025 | |
| Kyowa Kirin, INC. | $57.96 | 2025 | |
| Sumitomo Pharma America, INC. | $56.80 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $52.89 | 2024-2025 | Epkinly |
| Tempus Ai, INC | $51.74 | 2024 | Xt Cdx |
| Morphosys, US INC. | $51.68 | 2022-2024 | Monjuvi |
| Fennec Pharmaceuticals, INC. | $47.59 | 2024-2025 | Pedmark, Fyarro |
| Legend Biotech USA INC. | $42.76 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $42.03 | 2023 | Empaveli |
| Acrotech Biopharma INC. | $38.66 | 2022-2023 | Beleodaq |
| Servier Pharmaceuticals LLC | $37.87 | 2023 | |
| Cti Biopharma Corp. | $33.30 | 2023 | Vonjo |
| Csl Behring | $31.11 | 2023 | Idelvion, Afstyla |
| Janssen Pharmaceuticals, INC | $30.48 | 2020-2021 | |
| Beone Medicines USA, INC. | $30.40 | 2025 | Tevimbra |
| Adaptive Biotechnologies Corporation | $26.82 | 2024 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $23.90 | 2022 | |
| Tg Therapeutics, INC. | $22.76 | 2022 | |
| Amag Pharmaceuticals, INC. | $22.14 | 2022 | |
| Ge Healthcare | $21.70 | 2022 | |
| Corcept Therapeutics | $20.58 | 2025 | Korlym |
| G1 Therapeutics, INC. | $19.29 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $18.89 | 2023 | Pyrukynd |
| Clovis Oncology, INC. | $18.40 | 2020 | |
| Immunogen, INC. | $18.31 | 2023 | Elahere |
| Sanofi-Aventis U.S. LLC | $17.78 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.79 | 2023 | Givlaari |
| Epizyme, INC. | $16.37 | 2022 | |
| Spectrum Pharmaceuticals INC. | $15.35 | 2023 | Rolvedon |
| Adc Therapeutics America, INC. | $13.12 | 2023 | |
| Secura Bio, INC. | $12.99 | 2022 | |
| Global Blood Therapeutics, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.